Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Editas Medicine Stock Quote

Editas Medicine (NASDAQ: EDIT)

Price as of May 24, 2024, 12:41 p.m. ET

Editas Medicine Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
EDIT -38.31% -73.16% -23.12% -68%
S&P +28.01% +86.40% +13.26% +175%

Editas Medicine Company Info

Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.

News & Analysis

The Fool has written over 200 articles on Editas Medicine.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.